Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2010 May 20:263–270. doi: 10.1007/978-3-540-34406-3_25

Toxic Shock Syndromes

K B Laupland 4, H Dele Davies 5
Editors: Jordi Rello1, Marin Kollef2, Emili Díaz3, Alejandro Rodríguez1
PMCID: PMC7121343

Abstract

Staphylococcal toxic shock syndrome (TSS) was first described in seven children aged 8–17 years by Todd et al. in 1978 [1]. It shortly thereafter became well known as an illness of menstruating women who used tampons [2, 3]. The syndrome is characterized by rapid onset of fever, hypotension, and multisystem failure with desquamating rash occurring in convalescence [4]. The majority of early cases reported were menstrually associated (MTSS) but this has been changing with an increasing proportion of cases non-menstrually associated (NMTSS) [5].

Keywords: Kawasaki Disease, Necrotizing Fasciitis, Toxic Shock Syndrome, Staphylococcal Enterotoxin, Invasive Group

References

  • 1.Todd J., Fishaut M., Kapral F., Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978;2(8100):1116–1118. doi: 10.1016/S0140-6736(78)92274-2. [DOI] [PubMed] [Google Scholar]
  • 2.Davis J.P., Chesney P.J., Wand P.J., LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 1980;303(25):1429–1435. doi: 10.1056/NEJM198012183032501. [DOI] [PubMed] [Google Scholar]
  • 3.Shands K.N., Schmid G.P., Dan B.B., Blum D., Guidotti R.J., Hargrett N.T., Anderson R.L., Hill D.L., Broome C.V., Band J.D., et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980;303(25):1436–1442. doi: 10.1056/NEJM198012183032502. [DOI] [PubMed] [Google Scholar]
  • 4.Wharton M., Chorba T.L., Vogt R.L., Morse D.L., Buehler J.W. Case definitions for public health surveillance. MMWR Recomm Rep. 1990;39(RR-13):1–43. [PubMed] [Google Scholar]
  • 5.Kain K.C., Schulzer M., Chow A.W. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis. 1993;16(1):100–106. doi: 10.1093/clinids/16.1.100. [DOI] [PubMed] [Google Scholar]
  • 6.Cone L.A., Woodard D.R., Schlievert P.M., Tomory G.S. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987;317(3):146–149. doi: 10.1056/NEJM198707163170305. [DOI] [PubMed] [Google Scholar]
  • 7.Bartter T., Dascal A., Carroll K., Curley F.J. ‘Toxic strep syndrome’. A manifestation of group A streptococcal infection. Arch Intern Med. 1988;148(6):1421–1424. doi: 10.1001/archinte.148.6.1421. [DOI] [PubMed] [Google Scholar]
  • 8.Stevens D.L., Tanner M.H., Winship J., Swarts R., Ries K.M., Schlievert P.M., Kaplan E. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321(1):1–7. doi: 10.1056/NEJM198907063210101. [DOI] [PubMed] [Google Scholar]
  • 9.The Working Group on Severe Streptococcal Infections Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA. 1993;269(3):390–391. doi: 10.1001/jama.269.3.390. [DOI] [PubMed] [Google Scholar]
  • 10.Davies H.D., McGeer A., Schwartz B., Green K., Cann D., Simor A.E., Low D.E. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med. 1996;335(8):547–554. doi: 10.1056/NEJM199608223350803. [DOI] [PubMed] [Google Scholar]
  • 11.Hoge C.W., Schwartz B., Talkington D.F., Breiman R.F., Mac-Neill E.M., Englender S.J. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA. 1993;269(3):384–389. doi: 10.1001/jama.269.3.384. [DOI] [PubMed] [Google Scholar]
  • 12.Zurawski C.A., Bardsley M., Beall B., Elliott J.A., Facklam R., Schwartz B., Farley M.M. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin Infect Dis. 1998;27(1):150–157. doi: 10.1086/514632. [DOI] [PubMed] [Google Scholar]
  • 13.Laupland K.B., Davies H.D., Low D.E., Schwartz B., Green K., McGeer A. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics. 2000;105(5):E60. doi: 10.1542/peds.105.5.e60. [DOI] [PubMed] [Google Scholar]
  • 14.Schuchat A., Broome C.V. Toxic shock syndrome and tampons. Epidemiol Rev. 1991;13:99–112. doi: 10.1093/oxfordjournals.epirev.a036080. [DOI] [PubMed] [Google Scholar]
  • 15.Kaul R., McGeer A., Low D.E., Green K., Schwartz B. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med. 1997;103(1):18–24. doi: 10.1016/S0002-9343(97)00160-5. [DOI] [PubMed] [Google Scholar]
  • 16.Schlech W.F., 3rd, Shands K.N., Reingold A.L., Dan B.B., Schmid G.P., Hargrett N.T., Hightower A., Herwaldt L.A., Neill M.A., Band J.D., et al. Risk factors for development of toxic shock syndrome. Association with a tampon brand. JAMA. 1982;248(7):835–839. doi: 10.1001/jama.248.7.835. [DOI] [PubMed] [Google Scholar]
  • 17.Osterholm M.T., Davis J.P., Gibson R.W., Mandel J.S., Wintermeyer L.A., Helms C.M., Forfang J.C., Rondeau J., Vergeront J.M. Tri-state toxic-state syndrome study. I. Epidemiologic findings. J Infect Dis. 1982;145(4):431–440. doi: 10.1093/infdis/145.4.431. [DOI] [PubMed] [Google Scholar]
  • 18.Schwartz B., Gaventa S., Broome C.V., Reingold A.L., Hightower A.W., Perlman J.A., Wolf P.H. Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study. Rev Infect Dis. 1989;11(Suppl 1):S43–48. doi: 10.1093/clinids/11.supplement_1.s43. [DOI] [PubMed] [Google Scholar]
  • 19.Gaventa S., Reingold A.L., Hightower A.W., Broome C.V., Schwartz B., Hoppe C., Harwell J., Lefkowitz L.K., Makintubee S., Cundiff D.R., et al. Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis. 1989;11(Suppl 1):S28–34. doi: 10.1093/clinids/11.supplement_1.s28. [DOI] [PubMed] [Google Scholar]
  • 20.Osterholm M.T., Forfang J.C. Toxic-shock syndrome in Minnesota: results of an active-passive surveillance system. J Infect Dis. 1982;145(4):458–464. doi: 10.1093/infdis/145.4.458. [DOI] [PubMed] [Google Scholar]
  • 21.Latham R.H., Kehrberg M.W., Jacobson J.A., Smith C.B. Toxic shock syndrome in Utah: a case-control and surveillance study. Ann Intern Med. 1982;96(6):906–908. doi: 10.7326/0003-4819-96-6-906. [DOI] [PubMed] [Google Scholar]
  • 22.Davis J.P., Osterholm M.T., Helms C.M., Vergeront J.M., Wintermeyer L.A., Forfang J.C., Judy L.A., Rondeau J., Schell W.L. Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings. J Infect Dis. 1982;145(4):441–448. doi: 10.1093/infdis/145.4.441. [DOI] [PubMed] [Google Scholar]
  • 23.Chesney P.J., Davis J.P., Purdy W.K., Wand P.J., Chesney R.W. Clinical manifestations of toxic shock syndrome. JAMA. 1981;246(7):741–748. doi: 10.1001/jama.246.7.741. [DOI] [PubMed] [Google Scholar]
  • 24.Schlievert P.M., Tripp T.J., Peterson M.L. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000–2003 surveillance period. J Clin Microbiol. 2004;42(6):2875–2876. doi: 10.1128/JCM.42.6.2875-2876.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tierno P.M., Jr Reemergence of staphylococcal toxic shock syndrome in the United States since 2000. J Clin Microbiol. 2005;43(4):2032. doi: 10.1128/JCM.43.4.2032-2033.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Broome C.V. Epidemiology of toxic shock syndrome in the United States: overview. Rev Infect Dis. 1989;11(Suppl 1):S14–21. doi: 10.1093/clinids/11.supplement_1.s14. [DOI] [PubMed] [Google Scholar]
  • 27.Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685–694. doi: 10.1016/S1473-3099(05)70267-X. [DOI] [PubMed] [Google Scholar]
  • 28.O’Brien K.L., Beall B., Barrett N.L., Cieslak P.R., Reingold A., Farley M.M., Danila R., Zell E.R., Facklam R., Schwartz B., et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995–1999. Clin Infect Dis. 2002;35(3):268–276. doi: 10.1086/341409. [DOI] [PubMed] [Google Scholar]
  • 29.Eriksson B.K., Andersson J., Holm S.E., Norgren M. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis. 1998;27(6):1428–1436. doi: 10.1086/515012. [DOI] [PubMed] [Google Scholar]
  • 30.Ekelund K., Skinhoj P., Madsen J., Konradsen H.B. Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects. Clin Microbiol Infect. 2005;11(7):569–576. doi: 10.1111/j.1469-0691.2005.01169.x. [DOI] [PubMed] [Google Scholar]
  • 31.Kum W.W., Laupland K.B., See R.H., Chow A.W. Improved purification and biologic activities of staphylococcal toxic shock syndrome toxin 1. J Clin Microbiol. 1993;31(10):2654–2660. doi: 10.1128/jcm.31.10.2654-2660.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Parsonnet J., Gillis Z.A., Richter A.G., Pier G.B. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun. 1987;55(5):1070–1076. doi: 10.1128/iai.55.5.1070-1076.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Garbe P.L., Arko R.J., Reingold A.L., Graves L.M., Hayes P.S., Hightower A.W., Chandler F.W., Broome C.V. Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA. 1985;253(17):2538–2542. doi: 10.1001/jama.253.17.2538. [DOI] [PubMed] [Google Scholar]
  • 34.Bergdoll M.S., Crass B.A., Reiser R.F., Robbins R.N., Davis J.P. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet. 1981;1(8228):1017–1021. doi: 10.1016/S0140-6736(81)92186-3. [DOI] [PubMed] [Google Scholar]
  • 35.Schlievert P.M., Shands K.N., Dan B.B., Schmid G.P., Nishimura R.D. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis. 1981;143(4):509–516. doi: 10.1093/infdis/143.4.509. [DOI] [PubMed] [Google Scholar]
  • 36.Crass B.A., Bergdoll M.S. Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome. J Clin Microbiol. 1986;23(6):1138–1139. doi: 10.1128/jcm.23.6.1138-1139.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lee V.T., Chang A.H., Chow A.W. Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)-and non-TSS-associated Staphylococcus aureus isolates. J Infect Dis. 1992;166(4):911–915. doi: 10.1093/infdis/166.4.911. [DOI] [PubMed] [Google Scholar]
  • 38.Schlievert P.M. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet. 1986;1(8490):1149–1150. doi: 10.1016/S0140-6736(86)91859-3. [DOI] [PubMed] [Google Scholar]
  • 39.Hayes P.S., Graves L.M., Feeley J.C., Hancock G.A., Cohen M.L., Reingold A.L., Broome C.V., Hightower A.W. Production of toxic-shock-associated protein(s) in Staphylococcus aureus strains isolated from 1956 through 1982. J Clin Microbiol. 1984;20(1):43–46. doi: 10.1128/jcm.20.1.43-46.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Schlievert P.M., Blomster D.A. Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. J Infect Dis. 1983;147(2):236–242. doi: 10.1093/infdis/147.2.236. [DOI] [PubMed] [Google Scholar]
  • 41.Parsonnet J., Hansmann M.A., Delaney M.L., Modern P.A., Dubois A.M., Wieland-Alter W., Wissemann K.W., Wild J.E., Jones M.B., Seymour J.L., et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol. 2005;43(9):4628–4634. doi: 10.1128/JCM.43.9.4628-4634.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Musser J.M., Schlievert P.M., Chow A.W., Ewan P., Kreiswirth B.N., Rosdahl V.T., Naidu A.S., Witte W., Selander R.K. A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome. Proc Natl Acad Sci U S A. 1990;87(1):225–229. doi: 10.1073/pnas.87.1.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990;248(4959):1066. [PubMed] [Google Scholar]
  • 44.Proft T., Fraser J.D. Bacterial superantigens. Clin Exp Immunol. 2003;133(3):299–306. doi: 10.1046/j.1365-2249.2003.02203.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Llewelyn M., Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis. 2002;2(3):156–162. doi: 10.1016/S1473-3099(02)00222-0. [DOI] [PubMed] [Google Scholar]
  • 46.Kum W.W., Laupland K.B., Chow A.W. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol. 2000;46(2):171–179. doi: 10.1139/cjm-46-2-171. [DOI] [PubMed] [Google Scholar]
  • 47.Choi Y., Lafferty J.A., Clements J.R., Todd J.K., Gelfand E.W., Kappler J., Marrack P., Kotzin B.L. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med. 1990;172(3):981–984. doi: 10.1084/jem.172.3.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Cockerill F.R., 3rd, MacDonald K.L., Thompson R.L., Roberson F., Kohner P.C., Besser-Wiek J., Manahan J.M., Musser J.M., Schlievert P.M., Talbot J., et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA. 1997;277(1):38–43. doi: 10.1001/jama.277.1.38. [DOI] [PubMed] [Google Scholar]
  • 49.Bisno A.L., Brito M.O., Collins C.M. Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3(4):191–200. doi: 10.1016/S1473-3099(03)00576-0. [DOI] [PubMed] [Google Scholar]
  • 50.Talkington D.F., Schwartz B., Black C.M., Todd J.K., Elliott J., Breiman R.F., Facklam R.R. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun. 1993;61(8):3369–3374. doi: 10.1128/iai.61.8.3369-3374.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Hauser A.R., Stevens D.L., Kaplan E.L., Schlievert P.M. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol. 1991;29(8):1562–1567. doi: 10.1128/jcm.29.8.1562-1567.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Musser J.M., Hauser A.R., Kim M.H., Schlievert P.M., Nelson K., Selander R.K. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A. 1991;88(7):2668–2672. doi: 10.1073/pnas.88.7.2668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Yutsudo T., Murai H., Gonzalez J., Takao T., Shimonishi Y., Takeda Y., Igarashi H., Hinuma Y. A new type of mitogenic factor produced by Streptococcus pyogenes. FEBS Lett. 1992;308(1):30–34. doi: 10.1016/0014-5793(92)81043-L. [DOI] [PubMed] [Google Scholar]
  • 54.Mollick J.A., Miller G.G., Musser J.M., Cook R.G., Grossman D., Rich R.R. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest. 1993;92(2):710–719. doi: 10.1172/JCI116641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Watanabe-Ohnishi R., Low D.E., McGeer A., Stevens D.L., Schlievert P.M., Newton D., Schwartz B., Kreiswirth B., Kotb M. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J Infect Dis. 1995;171(1):74–84. doi: 10.1093/infdis/171.1.74. [DOI] [PubMed] [Google Scholar]
  • 56.Paris A.L., Herwaldt L.A., Blum D., Schmid G.P., Shands K.N., Broome C.V. Pathologic findings in twelve fatal cases of toxic shock syndrome. Ann Intern Med. 1982;96(6):852–857. doi: 10.7326/0003-4819-96-6-852. [DOI] [PubMed] [Google Scholar]
  • 57.Larkin S.M., Williams D.N., Osterholm M.T., Tofte R.W., Posalaky Z. Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases. Ann Intern Med. 1982;96(6):858–864. doi: 10.7326/0003-4819-96-6-858. [DOI] [PubMed] [Google Scholar]
  • 58.Forni A.L., Kaplan E.L., Schlievert P.M., Roberts R.B. Clinical and microbiological characteristics of severe group A streptococcus infections and streptococcal toxic shock syndrome. Clin Infect Dis. 1995;21(2):333–340. doi: 10.1093/clinids/21.2.333. [DOI] [PubMed] [Google Scholar]
  • 59.Chesney R.W., Chesney P.J., Davis J.P., Segar W.E. Renal manifestations of the staphylococcal toxic-shock syndrome. Am J Med. 1981;71(4):583–588. doi: 10.1016/0002-9343(81)90210-2. [DOI] [PubMed] [Google Scholar]
  • 60.Demeter S.L., Fuenning C., Klein J.J. Pleural effusion in toxic shock syndrome. Ann Intern Med. 1982;97(1):148–149. doi: 10.7326/0003-4819-97-1-148_2. [DOI] [PubMed] [Google Scholar]
  • 61.Rosene K.A., Copass M.K., Kastner L.S., Nolan C.M., Eschenbach D.A. Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med. 1982;96(6):865–870. doi: 10.7326/0003-4819-96-6-865. [DOI] [PubMed] [Google Scholar]
  • 62.Stamenkovic I., Lew P.D. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med. 1984;310(26):1689–1693. doi: 10.1056/NEJM198406283102601. [DOI] [PubMed] [Google Scholar]
  • 63.Laupland K.B., Dele Davies H. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr Cardiol. 1999;20(3):177–183. doi: 10.1007/s002469900436. [DOI] [PubMed] [Google Scholar]
  • 64.Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., Gea-Banacloche J., Keh D., Marshall J.C., Parker M.M., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004;30(4):536–555. doi: 10.1007/s00134-004-2210-z. [DOI] [PubMed] [Google Scholar]
  • 65.Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368–1377. doi: 10.1056/NEJMoa010307. [DOI] [PubMed] [Google Scholar]
  • 66.Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342(18):1301–1308 [DOI] [PubMed]
  • 67.Kress J.P., Pohlman A.S., O’Connor M.F., Hall J.B. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471–1477. doi: 10.1056/NEJM200005183422002. [DOI] [PubMed] [Google Scholar]
  • 68.Schiffl H., Lang S.M., Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002;346(5):305–310. doi: 10.1056/NEJMoa010877. [DOI] [PubMed] [Google Scholar]
  • 69.van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., Vlasselaers D., Ferdinande P., Lauwers P., Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345(19):1359–1367. doi: 10.1056/NEJMoa011300. [DOI] [PubMed] [Google Scholar]
  • 70.Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709. doi: 10.1056/NEJM200103083441001. [DOI] [PubMed] [Google Scholar]
  • 71.Doig C.J., Laupland K.B., Zygun D.A., Manns B.J. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C. Expert Opin Pharmacother. 2003;4(10):1789–1799. doi: 10.1517/14656566.4.10.1789. [DOI] [PubMed] [Google Scholar]
  • 72.Annane D., Sebille V., Charpentier C., Bollaert P.E., Francois B., Korach J.M., Capellier G., Cohen Y., Azoulay E., Troche G., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862–871. doi: 10.1001/jama.288.7.862. [DOI] [PubMed] [Google Scholar]
  • 73.Chesney P.J., Crass B.A., Polyak M.B., Wand P.J., Warner T.F., Vergeront J.M., Davis J.P., Tofte R.W., Chesney R.W., Bergdoll M.S. Toxic shock syndrome: management and long-term sequelae. Ann Intern Med. 1982;96(6):847–851. doi: 10.7326/0003-4819-96-6-847. [DOI] [PubMed] [Google Scholar]
  • 74.Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med. 1952;13(4):389–399. doi: 10.1016/0002-9343(52)90293-3. [DOI] [PubMed] [Google Scholar]
  • 75.Tanaka M., Hasegawa T., Okamoto A., Torii K., Ohta M. Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrob Agents Chemother. 2005;49(1):88–96. doi: 10.1128/AAC.49.1.88-96.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Stevens D.L., Gibbons A.E., Bergstrom R., Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158(1):23–28. doi: 10.1093/infdis/158.1.23. [DOI] [PubMed] [Google Scholar]
  • 77.Laupland K.B., Boucher P., Rotstein C., Cook D.J., Doig C.J. Intravenous immunoglobulin for severe infections: a survey of Canadian specialists. J Crit Care. 2004;19(2):75–81. doi: 10.1016/j.jcrc.2004.04.001. [DOI] [PubMed] [Google Scholar]
  • 78.Norrby-Teglund A., Ihendyane N., Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis. 2003;35(9):683–689. doi: 10.1080/00365540310015944. [DOI] [PubMed] [Google Scholar]
  • 79.Takei S., Arora Y.K., Walker S.M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91(2):602–607. doi: 10.1172/JCI116240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Skansen-Saphir U., Andersson J., Bjork L., Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol. 1994;24(4):916–922. doi: 10.1002/eji.1830240420. [DOI] [PubMed] [Google Scholar]
  • 81.Kaul R., McGeer A., Norrby-Teglund A., Kotb M., Schwartz B., O’Rourke K., Talbot J., Low D.E. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome — a comparative observational study. Clin Infect Dis. 1999;28(4):800–807. doi: 10.1086/515199. [DOI] [PubMed] [Google Scholar]
  • 82.Darenberg J., Ihendyane N., Sjolin J., Aufwerber E., Haidl S., Follin P., Andersson J., Norrby-Teglund A. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333–340. doi: 10.1086/376630. [DOI] [PubMed] [Google Scholar]
  • 83.Durongpisitkul K., Gururaj V.J., Park J.M., Martin C.F. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96(6):1057–1061. [PubMed] [Google Scholar]
  • 84.Laupland K.B., Conly J.M. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis. 2003;37(7):933–938. doi: 10.1086/377735. [DOI] [PubMed] [Google Scholar]
  • 85.Centers for Disease Control and Prevention Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis. 2002;35(8):950–959. doi: 10.1086/342692. [DOI] [PubMed] [Google Scholar]
  • 86.Smith A., Lamagni T.L., Oliver I., Efstratiou A., George R.C., Stuart J.M. Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis? Lancet Infect Dis. 2005;5(8):494–500. doi: 10.1016/S1473-3099(05)70190-0. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Critical Care are provided here courtesy of Nature Publishing Group

RESOURCES